Which pair represents SERMs used in menopause management?

Which pair represents SERMs used in menopause management?

• A. Tamoxifen and ospemifene
• B. Bazedoxifene and tamoxifen
• C. Raloxifene and ospemifene
• D. Raloxifene and bazedoxifene

Answer: (D)

SERMs have tissue-specific estrogen receptor effects, so in menopause management we use those that improve bone health and relieve vasomotor symptoms without stimulating the endometrium. Raloxifene acts as an estrogen-like effect in bone, helping maintain bone density and reduce fracture risk, while acting as an antagonist in breast and uterus. Bazedoxifene also blocks estrogen’s actions in breast and uterus and strengthens bone; when paired with estrogen it provides relief from hot flashes and protects bone without endometrial stimulation. These roles fit the common needs in postmenopausal care, making this pair the best representation of SERMs used in menopause management. Tamoxifen is mainly for breast cancer risk/treatment, and ospemifene is used for vaginal atrophy (dyspareunia); neither pairing aligns as the standard menopause-management duo.

SERMs have tissue-specific estrogen receptor effects, so in menopause management we use those that improve bone health and relieve vasomotor symptoms without stimulating the endometrium. Raloxifene acts as an estrogen-like effect in bone, helping maintain bone density and reduce fracture risk, while acting as an antagonist in breast and uterus. Bazedoxifene also blocks estrogen’s actions in breast and uterus and strengthens bone; when paired with estrogen it provides relief from hot flashes and protects bone without endometrial stimulation. These roles fit the common needs in postmenopausal care, making this pair the best representation of SERMs used in menopause management. Tamoxifen is mainly for breast cancer risk/treatment, and ospemifene is used for vaginal atrophy (dyspareunia); neither pairing aligns as the standard menopause-management duo.